James J. Vredenburgh

Zinc-Induced Copper Deficiency Myeloneuropathy Masquerading as Paraneoplastic Syndrome: A Case Report

Vladimir Osadchyi, Sarah N Van Antwerp, James J. Vredenburgh

Copper deficiency is a rare but reversible cause of myeloneuropathy, often overlooked in patients presenting with progressive neurological deficits. Excessive zinc intake, particularly from denture adhesives, can lead to copper depletion through competitive inhibition of intestinal absorption. We present the case of …

us (code pays fourni par la source)

Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.

Luiza Doro, Gonca Ozcan, James J. Vredenburgh, Emily F. Collier

316 Background: Molecular diagnosis of advanced non-small cell lung cancer (NSCLC) is critical to guide therapeutic decisions. Blood next generation sequencing (NGS) allows for non-invasive screening for targetable genetic abnormalities. Many studies have validated using the liquid biopsies to screen for resistant …

us (code pays fourni par la source)

Extraosseous Ewing Sarcoma in a 28-Year-Old Male: A Case Report and Literature Review

Vladimir Osadchyi, James J. Vredenburgh

Ewing sarcoma (ES) is an uncommon and highly aggressive bone malignancy that predominantly occurs in children and young adults. Extraosseous Ewing sarcoma (EES), an even rarer variant, can present in the soft tissues instead of bone. In this case report, we detail …

us (code pays fourni par la source)

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen et autres

PURPOSE: We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. PATIENTS AND METHODS: (with or without concomitant enzyme-inducing antiepileptic drugs, respectively) once every 2 weeks. Primary …

us (code pays fourni par la source)

Supplementary Table S3 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello et autres

Supplementary Table S3 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Supplementary Table S1 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello et autres

Supplementary Table S1 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello et autres

Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Supplementary Data from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke et autres

Web Extra Material - 2 tables and 3 figures

Figure A2 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke et autres

Figure A2 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke et autres

Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Figure A3 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke et autres

Figure A3 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke et autres

Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial